Overview of the global vaccine ecosystem

References

• Kremer M. Creating markets for new vaccines. Part I: rationale. Inno Policy Econ. 2000;1:35–72. doi: 10.1086/ipe.1.25056141
   Google Scholar
• Arnould R, DeBrock L. The application of economic theory to the vaccine market. Supplying Vaccines: An Economic Analysis Of Critical Issues (IOS Press). 1996;101–131.
   Google Scholar
• Shanks GD. Could ross river virus be the next zika? J Travel Med. 2019;26(5):26. doi: 10.1093/jtm/taz003
   Web of Science ®Google Scholar
• Poland GA. Vaccines against lyme disease: what happened and what lessons can we learn? Clin Infect Dis. 2011;52(Suppl 3):s253–8. doi: 10.1093/cid/ciq116
   PubMed Web of Science ®Google Scholar
• Wen FT, Malani A, Cobey S. The beneficial effects of vaccination on the evolution of seasonal influenza. bioRxiv. 2020;162545. doi: 10.1101/162545
   Google Scholar
• Arinaminpathy N, Ratmann O, Koelle K, et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc Natl Acad Sci U S A. 2012;109(8):3173–3177. doi: 10.1073/pnas.1113342109
   PubMed Web of Science ®Google Scholar
• Cobey S, Larremore DB, Grad YH, et al. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol. 2021;21(5):330–335. doi: 10.1038/s41577-021-00544-9
   PubMed Web of Science ®Google Scholar
• Basak P, Abir T, Al Mamun A, et al. A global study on the correlates of Gross Domestic Product (GDP) and COVID-19 vaccine distribution. Vaccines (Basel). 2022;10(2):266. doi: 10.3390/vaccines10020266
   PubMed Web of Science ®Google Scholar
• Christopher Auld M, Toxvaerd F. The great covid-19 vaccine rollout: behavioural and policy responses. Natl Inst Econ Rev. 2021;257:14–35. doi: 10.1017/nie.2021.23
   Web of Science ®Google Scholar
• Coronavirus (COVID-19) Vaccinations. Our World In Data [Internet]. [cited 2022 Feb16].Available from: https://ourworldindata.org/covid-vaccinations
   Google Scholar
• Asadu C. Nigeria to reject vaccine donations with short shelf lives. Associated Press. [cited 2021 Dec 14]. https://apnews.com/article/coronavirus-pandemic-health-africa-nigeria-d924cab165a324604c3b93a28cc4190d
   Google Scholar
• Hotez PJ, Pecoul B, Rijal S, et al. Eliminating the neglected tropical diseases: translational science and new technologies. PLoS Negl Trop Dis. 2016;10(3):e0003895. doi: 10.1371/journal.pntd.0003895
   PubMed Web of Science ®Google Scholar
• Department of Control of Neglected Tropical Diseases Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240010352
   Google Scholar
• Shih W. Bill & Melinda Gates Foundation: shaping the vaccine manufacturing ecosystem. Gates Open Res. 2019;3:1619.
   Google Scholar
• Bernasconi V, Kristiansen PA, Whelan M, et al. Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(1):65–73. doi: 10.1007/s00103-019-03061-2
   PubMed Web of Science ®Google Scholar
• Ball P The lightning-fast quest for COVID vaccines — and what it means for other diseases. Nature [Internet]. [2020 Dec]. Available from: https://www.nature.com/articles/d41586-020-03626-1
   Google Scholar
• Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development. Business Wire [Internet]. [2020 Apr 9]. Available from: https://www.businesswire.com/news/home/20200409005405/en/
   Google Scholar
• Policy Cures Research. G-FINDER: tracking funding for global health R&D. G-FINDER Data Portal [Internet]. [cited 2021 Oct 1]. Available from: https://gfinderdata.policycuresresearch.org/
   Google Scholar
• Adams B Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test. Fierce Biotech [Internet]. 2020 Jul 27. Available from: https://www.fiercebiotech.com/biotech/moderna-nabs-a-barda-billion-as-its-kickstarts-late-stage-pandemic-vaccine-test
   Google Scholar
• BioNTech. BioNTech announces new collaboration to develop HIV and tuberculosis programs. 2019. https://investors.biontech.de/news-releases/news-release-details/biontech-announces-new-collaboration-develop-hiv-and
   Google Scholar
• Prioritizing diseases for research and development in emergency contexts. World Health Organization (WHO) [Internet]. [cited 2022 Feb17]. Available from: https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts
   Google Scholar
• Better health moves humanity forward. PATH [Internet]. [cited 2022 Apr]. Available from: https://www.path.org/about/
   Google Scholar
• Singh K, Mehta S. The clinical development process for a novel preventive vaccine: an overview. J Postgrad Med. 2016;62(1):4–11. doi: 10.4103/0022-3859.173187
   PubMed Web of Science ®Google Scholar
• Grenham A, Villafana T. Vaccine development and trials in low and lower-middle income countries: key issues, advances and future opportunities. Hum Vaccin Immunother. 2017;13(9):2192–2199. doi: 10.1080/21645515.2017.1356495
   PubMed Web of Science ®Google Scholar
• Douglas RG, Samant VB. The Vaccine Industry. Vaccines. 7th ed. Elsevier; 2018;41–50.e1. doi: 10.1016/B978-0-323-35761-6.00004-3
   Google Scholar
• U.S. Department of Health & Human Services. Influenza vaccine development programs. Medical Countermeasures [Internet]. [cited 2022 Feb 17]. Available from: https://www.medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/influenza-vaccine-development-programs/
   Google Scholar
• Universal Influenza Vaccine Research. National Institute of Allergy and Infectious Diseases [Internet]. [cited2022 Feb 17]. Available from: https://www.niaid.nih.gov/diseases-conditions/universal-influenza-vaccine-research
   Google Scholar
• Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19. Business Wire [Internet]. [cited 2020 Jul 26]. Available from: https://www.businesswire.com/news/home/20200726005025/en/
   Google Scholar
• How we work. Bill & Melinda Gates Foundation [Internet]. [cited 2022 Feb 17]. Available from: https://www.gatesfoundation.org/about/how-we-work
   Google Scholar
• Who we are. Wellcome [Internet]. [cited 2022 Feb 17]. Available from: https://wellcome.org/who-we-are
   Google Scholar
• Somauroo J Malaria vaccine 30 years and $1 billion in the making now deployed in third country. Forbes [Internet]. [cited 2019 Sep 24]. Available from: https://www.forbes.com/sites/jamessomauroo/2019/09/24/malaria-vaccine-30-years-and-1-billion-in-the-making-now-deployed-in-third-country/?sh=96d57ce2583f
   Google Scholar
• A global coalition for a global problem. CEPI [Internet]. [cited 2022 Feb 17]. Available from: https://cepi.net/about/whoweare/
   Google Scholar
• Watson M, de Goër E F. Are good intentions putting the vaccination ecosystem at risk? Hum Vaccin Immunother. 2016;12(9):2469–2474. doi: 10.1080/21645515.2016.1172162
   PubMed Web of Science ®Google Scholar
• Government, Sanofi officials unveil $925M in vaccine funding in Toronto. CBC News [Internet]. [cited 2021 Mar31]. Available from: https://www.cbc.ca/news/canada/toronto/flu-vaccine-production-north-york-toronto-sanofi-1.5970870
   Google Scholar
• Kim JH, Hotez P, Batista C, et al. Operation warp speed: implications for global vaccine security. Lancet Glob Health. 2021;9(7):e1017–e1021. doi: 10.1016/S2214-109X(21)00140-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 vaccines with WHO emergency use listing. https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued
   Google Scholar
• U.S. Department of Health & Human Services. International influenza vaccine manufacturing capacity building program. Medical Countermeasures [Internet]. [cited 2022 Feb]. Available from: https://www.medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/international-influenza-vaccine-manufacturing-capacity-building-program/
   Google Scholar
• Surveillance in emergencies. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https://www.who.int/emergencies/surveillance
   Google Scholar
• Institute of Medicine (US) Forum on Emerging Infections. Davis JR, Lederberg J, editors. Public health systems and emerging infections: assessing the capabilities of the public and private sectors. Washington (DC): National Academy Press (US); 2000. doi: 10.17226/9869
   Google Scholar
• Budhiraja S, Akinapelli R. Pharmacovigilance in vaccines. Indian J Pharmacol. 2010;42(2):117. doi: 10.4103/0253-7613.64488
   PubMed Web of Science ®Google Scholar
• Murray J, Cohen AL. Infectious Disease Surveillance. International Encyclopedia Public Health. 2nd ed. Oxford: Academic Press; 2017:222–229. doi: 10.1016/B978-0-12-803678-5.00517-8
   Google Scholar
• Nationally Notifiable Diseases. Centers For Disease Control And Prevention (CDC) [Internet]. [cited 2022 Feb 17]. Available from: https://www.cdc.gov/healthywater/statistics/surveillance/notifiable.html
   Google Scholar
• European Medicines Agency (EMA). Risk management plans. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pharmacovigilance/risk-management/risk-management-plans
   Google Scholar
• Centers for Disease Control and Prevention. Vaccine safety datalink (VSD). https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html
   Google Scholar
• CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Definitions and applications of terms for vaccine pharmacovigilance. Geneva: The Council for International Organizations of Medical Sciences (CIOMS); 2012.
   Google Scholar
• Arthur RR, Leduc JW, Hughes JM Surveillance for Emerging Infectious Diseases and Bioterrorism Threats . Tropical Infectious Diseases Second Edition . 2006 195–200 doi:10.1016/B978-0-443-06668-9.50020-X ;1 (Philadelphia: Churchill Livingstone).
   Google Scholar
• Where We Work. In: Centers for Disease Control and Prevention (CDC) [Internet]. [cited 2022 Feb17]. Available from: https://www.cdc.gov/globalhivtb/where-we-work/index.html
   Google Scholar
• Carroll D, Daszak P, Wolfe ND, et al. The global virome project. Science. 2018;359(6378):872–874. doi: 10.1126/science.aap7463
   PubMed Web of Science ®Google Scholar
• Morse SS. Global infectious disease surveillance and health intelligence. Health Aff. 2007;26(4):1069–1077. doi: 10.1377/hlthaff.26.4.1069
   Web of Science ®Google Scholar
• International Health Regulations. In: World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https://www.who.int/health-topics/international-health-regulations#tab=tab_1
   Google Scholar
• Public health surveillance for COVID-19: interim guidance. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.1
   Google Scholar
• Duclos P. National immunization technical advisory groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010;28(Suppl 1):A18–25. doi: 10.1016/j.vaccine.2010.02.027
   PubMed Web of Science ®Google Scholar
• Piso B, Wild C. Decision support in vaccination policies. Vaccine. 2009;27(43):5923–5928. doi: 10.1016/j.vaccine.2009.07.105
   PubMed Web of Science ®Google Scholar
• Harmon SHE, Faour D, MacDonald N. National immunization technical advisory groups (NITAGs): a schema for evaluating and comparing foundation instruments and NITAG operations. Med Law Int. 2021;21(1):69–98. doi: 10.1177/09685332211002594
   Google Scholar
• Duclos P, Dumolard L, Abeysinghe N, et al. Progress in the establishment and strengthening of national immunization technical advisory groups: analysis from the 2013 WHO/UNICEF joint reporting form, data for 2012. Vaccine. 2013;31(46):5314–5320. doi: 10.1016/j.vaccine.2013.08.084
   PubMed Web of Science ®Google Scholar
• Kamiya H, Okabe N. Leadership in immunization: the relevance to Japan of the USA experience of the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP). Vaccine. 2009;27(11):1724–1728. doi: 10.1016/j.vaccine.2009.01.030
   PubMed Web of Science ®Google Scholar
• Smith JC. The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP). Vaccine. 2010;28(Suppl 1):A68–75. doi: 10.1016/j.vaccine.2010.02.037
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, et al. The advisory Committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922–1924. doi: 10.15585/mmwr.mm6950e2
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, et al. The advisory Committee on immunization practices’ interim recommendation for use of Moderna COVID-19 vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653–1656. doi: 10.15585/mmwr.mm695152e1
   PubMed Web of Science ®Google Scholar
• Ba-Nguz A, Shah A, Bresee JS, et al. Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the task force for global health’s Partnership for influenza vaccine introduction. Vaccine. 2019;37(28):3646–3653. doi: 10.1016/j.vaccine.2019.05.046
   PubMed Web of Science ®Google Scholar
• Bell S, Blanchard L, Walls H, et al. Value and effectiveness of national immunization technical advisory groups in low-and middle-income countries: a qualitative study of global and national perspectives. Health Policy Plan. 2019;34(4):271–281. doi: 10.1093/heapol/czz027
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Regional technical advisory groups on immunization (RITAG). World Health Organization (WHO) [Internet]. [cited 2023 Feb 8] Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/regional-technical-advisory-groups-on-immunization-(ritag)
   Google Scholar
• WHO Lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. World Health Organization (WHO) [Internet]. [cited 2021 May 7]. Available from: https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
   Google Scholar
• Sahar N, Lee O, Hoffman SJ, et al. Overview of key legal, political, and social challenges facing global vaccination efforts. Imaginations: Journal Of Cross-Cultural Image Studies/Imaginations: Revue D’études Interculturelles de L’image. 2020;11(2):127–153. doi: 10.17742/IMAGE.IN.11.2.9
   Google Scholar
• Vaccine Development—101. In: US Food and Drug Administration [Internet]. [cited 2022 Feb17]. Available from: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101
   Google Scholar
• Partnerships and Collaboration. US Food And Drug Administration [Internet]. [cited 2022 Feb 17]. Available from: https://www.fda.gov/international-programs/partnerships-and-collaboration
   Google Scholar
• Gomez PL, Robinson JM, Rogalewicz JA. Vaccine manufacturing. Vaccines 6th ed. London: W.B. Saunders; 2013:44–57. doi: 10.1016/B978-1-4557-0090-5.00019-7
   Google Scholar
• World Health Organization (WHO). AVAREF overview. World Health Organization (WHO) [Internet]. [cited 2023 Feb 8]. Available from: https://www.afro.who.int/health-topics/immunization/avaref/overview
   Google Scholar
• Mission: Harmonisation for Better Health. International Council For Harmonisation (ICH) [Internet]. [cited 2022 Feb 17] Available from: https://www.ich.org/page/mission
   Google Scholar
• World Health Organization (WHO). WHO-Listed authority (WLA). [cited 2023 Mar 23]. Available from: https://www.who.int/initiatives/who-listed-authority-reg-authorities
   Google Scholar
• Welcome to Vaccines Prequalification. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https://extranet.who.int/pqweb/vaccines
   Google Scholar
• Medicines for use outside the European Union. European Medicines Agency [Internet]. [cited 2022 Feb 17].Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/medicines-use-outside-european-union
   Google Scholar
• Khadem Broojerdi A, Baran Sillo H, Ostad Ali Dehaghi R, et al. The World health Organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Front Med. 2020;7:457. doi: 10.3389/fmed.2020.00457
   Web of Science ®Google Scholar
• Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis. 2004;38(10):1440–1446. doi: 10.1086/420748
   PubMed Web of Science ®Google Scholar
• About the Vaccines for Children Program (VFC). Centers For Disease Control And Prevention (CDC) [Internet]. [cited 2022 Apr6]. Available from: https://www.cdc.gov/vaccines/programs/vfc/about/index.html
   Google Scholar
• Mulligan K, Snider JT, Arthur P, et al. Examination of universal purchase programs as a driver of vaccine uptake among US States, 1995–2014. Vaccine. 2018;36(28):4032–4038. doi: 10.1016/j.vaccine.2018.05.103
   PubMed Web of Science ®Google Scholar
• Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. U.S. Department Of Health And Human Services (HHS) [Internet]. [cited 2022 Apr 6]. Available from: https://www.hhs.gov/about/news/2021/02/11/biden-administration-purchases-additional-doses-covid-19-vaccines-from-pfizer-and-moderna.html
   Google Scholar
• PAHO Revolving Fund. Pan American Health Organization (PAHO) [Internet]. [cited 2022 Feb17]. Available from: https://www.paho.org/en/revolvingfund
   Google Scholar
• COVAX. Gavi [Internet]. [cited 2022 Feb 17].Available: https://www.gavi.org/covax-facility?gclid=Cj0KCQjwwNWKBhDAARIsAJ8HkhdpvIUKB83PXcyP5vzZkDDTrQcxhftCAJ1SBBBvjjJOhJvm3WAbzxEaAm60EALw_wcB
   Google Scholar
• COVAX: ensuring global equitable access to COVID-19 vaccines. UNICEF [Internet]. [cited 2022 Apr]. Available from: https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines
   Google Scholar
• de Bolle M COVAX is failing to halt the COVID-19 pandemic: here’s why, and how to fix it. The Conversation [Internet]. [cited 2021 Jun 8]. Available from: https://theconversation.com/covax-is-failing-to-halt-the-covid-19-pandemic-heres-why-and-how-to-fix-it-162146
   Google Scholar
• Ducharme J COVAX was a great idea, but is now 500 million doses short of its vaccine distribution goals. What Exactly went wrong? Time[Internet]. 2021. https://time.com/6096172/covax-vaccines-what-went-wrong/
   Google Scholar
• de Bengy Puyvallée A, Storeng KT. COVAX, vaccine donations and the politics of global vaccine inequity. Global Health. 2022;18(1):26. doi: 10.1186/s12992-022-00801-z
   PubMed Web of Science ®Google Scholar
• Smith J, Lipsitch M, Almond JW. Vaccine production, distribution, access, and uptake. Lancet. 2011;378(9789):428–438. doi: 10.1016/S0140-6736(11)60478-9
   PubMed Web of Science ®Google Scholar
• Immunization. UNICEF [Internet]. [cited 2022 Feb17]. Available from: https://www.unicef.org/immunization
   Google Scholar
• Anyiam-Osigwe T. The long view: keeping vaccines cool with cold chain. Gavi [Internet]. [2021 May 31]. Available from: https://www.gavi.org/vaccineswork/long-view-keeping-vaccines-cool-cold-chain?gclid=CjwKCAjwy7CKBhBMEiwA0Eb7agfoM7WSBp-sKmrDHHjfGLtG8g1Ri2aI_jIbgcjaaksF1xrO3HeXCBoCFsYQAvD_BwE
   Google Scholar
• Africa Centres for Disease Control and Prevention (Africa CDC). African vaccine acquisition trust delivers 12 000 doses of COVID-19 vaccine to the african union. 2021. https://africacdc.org/news-item/african-vaccine-acquisition-trust-delivers-12-000-doses-of-covid-19-vaccine-to-the-african-union/
   Google Scholar
• The african union’s african vaccine acquisition trust (AVAT) initiative. UNICEF [Internet]. [cited 2022 Feb 17]. Available from: https://www.unicef.org/supply/african-unions-african-vaccine-acquisition-trust-avat-initiative
   Google Scholar
• de Figueiredo A, Simas C, Karafillakis E, et al. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898–908. doi: 10.1016/S0140-6736(20)31558-0
   PubMed Web of Science ®Google Scholar
• MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4164. doi: 10.1016/j.vaccine.2015.04.036
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Ten Threats to global health in 2019. 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
   Google Scholar
• Oduwole EO, Pienaar ED, Mahomed H, et al. Current tools available for investigating vaccine hesitancy: a scoping review protocol. BMJ Open. 2019;9(12):e033245. doi: 10.1136/bmjopen-2019-033245
   PubMed Web of Science ®Google Scholar
• Forum on Drug Discovery, Development, andTranslation, Board on Health Sciences Policy, Institute of Medicine (IOM). International regulatory Harmonization amid globalization of Drug development: workshop summary. Weisfeld V, Lustig TA, editors. (WA) (DC): National Academies Press (US); 2013.
   Google Scholar